Showing 651-660 of 1564 results for "".
The Battle of Biostimulators: PLLA vs hyperdilute CaHA
https://modernaesthetics.com/ma-issues-index/july-august-2025/biostimulators-PLLA-vs-HyperdiluteCaHA/36663/Key takeaways from Dr. Kay Durairaj's YoungMD Connect workshopAddressing COPD Exacerbations With Urgency
https://reachmd.com/programs/medical-industry-feature/addressing-copd-exacerbations-with-urgency/24225/Hear about the burden of chronic obstructive pulmonary disease (COPD) exacerbations and the role of early diagnosis and proactive care in addressing them.Illuminating AOX Serum from ZO Skin Health
https://modernaesthetics.com/topics/skincare/illuminating-aox-serum-from-zo-skin-health/35200/Nicotinamide for COVID-19 Recovery: Restoring Metabolic Balance
https://reachmd.com/programs/clinicians-roundtable/nicotinamide-for-covid-19-recovery-restoring-metabolic-balance/36410/Scientific Advancements Leading to New Options to Manage Aesthetic Concerns
https://modernaesthetics.com/topics/injectables/scientific-advancements-leading-to-new-options-to-manage-aesthetic-concerns/35185/Updates on some of the latest developments in minimially invasive aestheticsAre All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/Join us to learn about the emerging data with VMAT2 inhibitors for the treatment of tardive dyskinesia.Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/Join us to learn about the diagnosis of NPS associated with Alzheimer’s disease, as well as current and emerging agents for treatment.The Unmet Need in 1L HR+/HER2− Advanced Breast Cancer
https://reachmd.com/programs/medical-industry-feature/the-unmet-need-in-1l-hrher2-advanced-breast-cancer/36170/Over the past 50 years, endocrine therapies have improved patient outcomes in HR-positive, HER2-negative advanced breast cancer.1 However, after first-line treatment with an endocrine therapy plus a CDK4/6 inhibitor, the current standard of care, progression-free survival typically decreases with thAdvancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
https://reachmd.com/programs/cme/advancing-trop-2-targeted-adcs-in-hr-breast-cancer-navigating-today-and-shaping-tomorrow/29264/Learn about the role of TROP-2-targeted ADC therapy in the treatment of endocrine-resistant, hormone-positive, HER2-negative breast cancer.Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
https://reachmd.com/programs/cme/current-standards-and-future-opportunities-for-adcs-in-advancedmetastatic-triple-negative-breast-cancer/14551/Are you ready and willing to change your treatment approach for your patients with TNBC? Our experts break down the guidelines to get you on track.